RxDoctor Payments Data

Onkarjit Marwah, MD

Cardiovascular Disease · Glendale, CANPI 1255314514

Payments from drug & device makers

$24,867in general payments, 2019–2025

Across 329 payments — averaging $75.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$7K
  • Abbott$6K
  • Abiomed$2K
  • Medtronic$995
  • Penumbra, Inc.$976
  • Boston Scientific$883
  • plus $7K from 28 others

What the payments were for

  • Speaking & faculty fees$4,29017%
  • Travel & lodging$2,1088%
  • Food & beverage$17,89372%
  • Education$5772%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,867 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$539,671
Medicare patients
1,198
Services billed
8,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan95$1,286,902
UptraviSelexipag50$1,038,112
EliquisApixaban507$350,148
EntrestoSacubitril/Valsartan325$299,789
XareltoRivaroxaban236$181,533
BrilintaTicagrelor201$102,529
MultaqDronedarone Hcl76$68,509
Repatha SureclickEvolocumab96$57,606
FarxigaDapagliflozin Propanediol51$50,197
VerquvoVericiguat65$49,582
VascepaIcosapent Ethyl195$49,324
Sildenafil Citrate65$27,832
JardianceEmpagliflozin26$23,220
EffientPrasugrel Hcl18$13,920
Icosapent Ethyl83$11,786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$7,333$2,325,013145 claims
NovartisEntresto$302$299,789325 claims
Johnson & JohnsonXarelto$367$181,533236 claims
AstraZenecaBrilinta, Farxiga$612$152,726252 claims
MerckVerquvo$415$49,58265 claims
Boehringer IngelheimJardiance$22$23,22026 claims
Esperion Therapeutics, Inc.Nexlizet$115$8,16821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →